Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|February 5, 2002
Current status and new developments with galantamine in the treatment of Alzheimer's diseaseP TariotJournal of the American Geriatrics Society|March 1, 1996
Minimum Data Set Plus (MDS+) scores compared with scores from five rating scalesK Frederiksen, P Tariot, E De JongheNew Directions for Mental Health Services|January 1, 1997
Treatment of agitation in dementiaP Tariot, S E Gaile, N A Castelli, et al.Clinical Neuropharmacology|August 1, 1989
Carbamazepine-induced ticsR Kurlan, J Kersun, J Behr, et al.Psychiatry Research|October 1, 1987
Function of the adrenal cortex in patients with major depressionN H Kalin, G Dawson, P Tariot, et al.Psychopharmacology|January 1, 1985
Scopolamine challenges in Alzheimer's diseaseT Sunderland, P Tariot, D L Murphy, et al.The Journal of Prevention of Alzheimer'S Disease|October 10, 2018
Pimavanserin: Potential Treatment For Dementia-Related PsychosisJ Cummings, C Ballard, P Tariot, et al.Alzheimer Disease and Associated Disorders|January 1, 1996
Measures of psychiatric symptoms in Alzheimer patients: a reviewM F Weiner, E Koss, K V Wild, et al.Alzheimer Disease and Associated Disorders|January 1, 1997
A longitudinal study of behavioral pathology across five levels of dementia severity in Alzheimer's disease: the CERAD Behavior Rating Scale for Dementia. The Alzheimer's Disease Cooperative StudyM B Patterson, J L Mack, J A Mackell, et al.International Journal of Geriatric Psychiatry|July 24, 2001
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?B Winblad, H Brodaty, S Gauthier, et al.Pageof 2